Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 6, 2007, Pages 537-543

  Yoneda, Ken Y ^a,b   Shelton, David K ^a   Beckett, Laurel A ^a   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute respiratory distress syndrome; Epidermal growth factor receptor; Erlotinib; Interstitial lung disease; Non small cell lung cancer; Tarceva; TRIBUTE; Tyrosine kinase inhibitor

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CORTICOSTEROID; ERLOTINIB; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; BIOPSY; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG MEGADOSE; DYSPNEA; FATALITY; FEMALE; HISTOPATHOLOGY; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; LUNG INFECTION; LUNG NON SMALL CELL CANCER; MALE; MEDICAL SPECIALIST; MULTIPLE CYCLE TREATMENT; ONCOLOGY; PRIORITY JOURNAL; PULMONOLOGY; RADIOLOGIST; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; THORAX RADIOGRAPHY; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 34447126891     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318060d329     Document Type: Article

References (30)

1. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167.
2. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 2003;284:31-53.
3. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002;110:669-672.
4. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-2246.
5. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
6. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
8. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
9. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
10. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-794.
11. Herbst RS, Prager D, Hermann L, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
12. Gatzemeier U, Pluzanska A, Szcaesna A, Kaukel E. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell cancer (NSCLC). Proc Am Soc Clin Oncol 2004 (post-meeting edition).
13. Inomata S, Takahashi H, Nagata G, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 2004;15:461-467.
14. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-306.
15. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005;10:461-466.
16. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004. 91(Suppl):S18-S23.
17. Endo M, Johkoh T, Kimura K, Yamamoto N. Imaging of gefitinibrelated interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 2006;52:135-140.
18. Herbst RS, Prager D, Hermann R. TRIBUTE - A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:619s.
19. Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol 2005;23:5856-5858.
20. Forsythe B Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf 2004;27:1081-1092.
21. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-2556.
22. Kris MG, Sandler A, Miller V. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchoalveolar carcinoma (BAC) (Abstract 7062). Proc Am Soc Clin Oncol 2004;23:628.
23. Johnson BE, Lucca J, Rabin M. Preliminary results from a phase II study of the EGFR tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma. Proc Am Soc Clin Oncol 2004.
24. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Muller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002;57:292-299.
25. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218.
26. Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003;22:179-181.
27. Cersosimo RJ. Gefitinib: an adverse effects profile. Expert Opin Drug Saf 2006;5:469-479.
28. Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 2005;28:103-113.
29. Kataoka K, Taniguchi H, Hasegawa Y, et al. Interstitial lung disease associated with gefitinib. Respir Med 2006;100:698-704.
30. Yoneda K. Interstitial lung disease (ILD) with EGFR TKIs. Presented at the 7th International Lung Cancer Congress (Workshop), Maui, HI, 2006.